Update of Anemia management in chronic kidney disease What is still missing.

Slides:



Advertisements
Similar presentations
Anaemia management in people with chronic kidney disease
Advertisements

Unexplained Anaemia Acute Medicine Update
Network 11 Quality Update Chris Singer, MAN, RN, CNN December 4, 2008.
ANEMIA IN PREGNANCY O+G Update 2014 Hospital Sarikei.
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Anemia an enigma in chronic kidney disease Mohammad Asgar Khan, MD.
Journal Club EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events – EVOLVE NEJM Dec 2012 Yuvaraj Thangaraj, M.D. Nephrology Fellow Division.
The Use of EPO-Stimulating Agents in Heart Failure Nora Sharaya, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health Network This.
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Clinical Case Presentation #5 Iron Deficiency Anemia Building Blocks of Life.
Anemia in chronic kidney disease
Iron Deficiency Anemia General Medicine Conference August 11, 2008.
Anemia in Transplantation Yvette Talusan- Tomacruz, M.D.
Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.
Faint is not a description of color Faint is a description of LIFE.
Anemia and CKD An Update
Pablo M. Bedano M.D. Community Regional Cancer Care.
Epoetin Alfa & Increased Mortality Maria Shin, Pharm.D. Pharmacy Resident (PGY-1) Kingsbrook Jewish Medical Center Clinical Instructor of Pharmacy Practice.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Iron Repletion in ESRD Saleem Bharmal 2/9/10.
IRON 7 mg/1000 cal in diet; 10% absorbed Heme iron absorbed best, Fe 2+ much better than Fe 3+ –Some foods, drugs enhance and some inhibit absorption of.
Iron in patients with chronic kidney disease
Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.
ROLE OF IRON STORES IN ANEMIA
IRON DEFICIENCY ANEMIA
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
How to manage anaemia in HD patients
Causes Blood loss – usually from uterus or GI tract Increased demands such as growth and pregnancy Decreased absorption – post gastrectomy, Coeliac disease.
Commonly seen 30% of non hospitalized CHF 50% of hospitalized CHF patients Increased mortality Increased morbidity Hospitalization Associated.
Dr. Sadia Batool Shahid PGT-M-Phil, Pharmacology
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
ANEMIA September 17 th, 2011 Debra Wells BSN, RN, CNN.
 Stored in the body as ferritin  Deficiency result from negative iron balance due to depletion of stores and/or inadequate intake.  Iron deficiency.
The graph is based on data submitted to the WHO as of June Global Prevalence of Hepatitis C Virus.
Research Project for Dialysis Patients with a Hgb >13 for 2005 Researched, Edited, and Presented by Mindy Huttu, Anatole Besarab, and Stan Frinak.
Hematological System KNH 413. Nutritional Anemias Macrocytic –B12, B9, B1, pyridoxine (B??) Decreased ability to synthesize new cells and DNA Microcytic.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
IRON DEFICIENCY ANEMIA/ ANEMIA OF CHRONIC DISEASE
Management of Anemia in CKD Patients 2012 KDIGO Update Dr. Shahram Taheri.
Iron Deficiency Anemia Iron Metabolism: Iron Metabolism: IRON INTAKE (Dietary) - “ average ” adult diet = mg Fe/day - absorption = 5-10% (0.5-2 mg/day)
Chronic Kidney Disease (CKD) Healthy Kansans 2010.
Anemia in Hemodialysis 1. 2 Etiology The anemia of chronic kidney disease (CKD) is primarily due to insufficient production of the glycoprotein hormone.
Iron deficiency screening at Heart Failure Clinic Abela Mark, Karl Sapiano Cardiology Conference 2014.
Aetiology of preoperative anaemia in patients undergoing elective cardiac surgery Jacob Abhrahm 1,Romi Sinha 2,Kathryn Robinson 3, David Cardone 1 1 Department.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Erythropoietin for anemia of CRF.
What we are missing 2012 KDIGO guideline. Anemia.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
By: Ahmad Harith Zabidi Azhar Nik Muhammad Farhan Zulkifli Shahrizam Tahir Ahmad Nadzmi Mahfuz.
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
Section 4: Managing progression of CKD
Mansoura International Hospital Mansoura International Hospital
Individualized Medicine and Biophysical System Dynamics
Algorithm for management of anemia of CKD in adults
Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN
Absorption, transport, and storage of iron
QIP: Intravenous Iron Service for Renal Anaemia at SaTH
Chapter 2: Clinical Indicators and Preventive Care
Chronic kidney disease and pre-dialysis
Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018
ANAEMIA IN PREGNANCY AHMED ABDULWAHAB.
New and Emerging Management Options for Anemia in CKD
A. Besarab  Kidney International  Volume 69, Pages S13-S18 (May 2006)
Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.
Volume 2: End-Stage Renal Disease
The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle  Douglas S. Fuller, MS, Ronald L. Pisoni,
Presentation transcript:

update of Anemia management in chronic kidney disease What is still missing

This way What makes the standards Guidelines Own experience Economic status

STILL MISSING Iron management Aim of treatment Statistics Early Transferal

Strategies for treating renal anemia Time or GFR Prevention Dialysis Earlier start Higher target Hb (g/dl) Hb Sweet Spot

Low Hb Tiredness and exhaustion Poor quality of life High transfusion rate Higher rate of death and CV complications Death and CV Complications Hypertension Faster progression of CKD Increased Risk of Stroke Vascular access thrombosis High Hb Hb Trade Offs

March 9, 2007

The Hemoglobin Sweet Spot Hb g/dL Risk 100% 50%

March 9, 2007

Step 1 Insert the TEST CARD Step 2 Apply the SAMPLE Step 3 Read the RESULT in 2 min

STILL MISSING Iron management Aim of treatment Statistics Early Transferal

Pro-inflammatory cytokines (IL-1, TNFα, IL-6, IFNγ) EPO + + Iron Apoptosis ─ Hepcidin  Fe absorption  Fe transport  Fe availability (EPO-R, Tf, TfR, Ferriportin, DMT-1) ─ Erythropoiesis

Occult G-I losses Peptic ulceration Blood sampling Dialyser losses Concurrent meds. – e.g. aspirin Heparin on dialysis Poor appetite Poor G-I absorption Concurrent medication – e.g. omeprazole Food interactions REDUCED INTAKEINCREASED LOSSES Why are CKD patients prone to develop iron deficiency

Am J Nephrology 2007

Non – haematological benefits of iron Iron Haemoglobin Physical Performance Thermoregulation Cognitive Function Restless legs Immune function

Clinical issues in iron deficiency in CKD Assessing iron status Oral versus intravenous medication Iron management in CKD

Assessing iron status Quantification of iron stores Measurement of available iron in blood Assessment of iron uptake and utilisation by marrow

Assessing iron status Quantification of iron stores Serum ferritin, bone marrow stainable iron Serum ferritin is acute phase protein

Assessing iron status Measurement of available iron in blood Transferrin saturation = 100 X serum iron serum total iron binding capacity

Assessing iron status Assessment of iron uptake and utilisation by marrow: % hypochromic red cells, RBC zinc protophoryin

Recommended Targets for Iron Status in CKD K-DOQIEuropean Best practice Guidelines National Institute for Clinical Excellence (NICE) Serum Ferritin ceiling >100ng/ml (non- dialysis). >200ng/ml (dialysis) Not routinely>500ng/ ml >100ng/ml (target ng/ml) >100ng/ml target ng/ml Transferrin Saturation (TSAT) >20% >20% unless ferritin>800ng/ml % Hypochromic Red Cells ---<10% target <2.5% 800ng/ml CHr – reticulocyte haemoglobin >29pg/cell>29pg/cell target = 35pg/cell

Frequency of iron status tests: 1- Every month during initial ESA treatment 2- At least every 3 months during stable ESA treatment or in patients with HD-CKD not treated with an ESA © 2006 National Kidney Foundation, Inc. NKF KDOQI GUIDELINES

< 100 ng/ml ng/ml ng/ml (200 ng/ml ) ng/ml > 800 ng/ml (400 ng/ml) invalid Ferritin assessment in 10 min

Oral Iron I.V. Iron Vs

FDA reported allergic reactions to IV iron: Jan 1997-Sep 2002 Reports/million 100 mg dose equivalents Bailie et al. NDT 2005,20,

Heme – Iron polypeptide Derived from bovine haemoglobin Oral bioavailabilty 10 times greater than conventional oral iron Reduced GI side effects

Heme – Iron polypeptide

STILL MISSING Iron management Aim of treatment Statistics Early Transferal

Statistics Incidence: Measure of new patients entering ESRD/Dialysis Prevalence: Measure of patients undergoing dialysis Africa: Incidence ~ ? P.M.P ME Prevalence ~ ? P.M.P A need for more accurate data in most of the countries to plan for the future

STILL MISSING Iron management Aim of treatment Statistics Early Transferal

Transferal & Decision to treat 65% transferred when in need for urgent dialysis ( KSA) How many patients treated for their anemia in our region? How many patients reach target Hgb in our region?

More frequent monitor for Hb &iron limiting ESA when Hb over 12g/dl Optimum iron therapy lower ESA dose Conclusion A need for more accurate data related to Incidence &Prevalence Screening program for early transferral is needed

Thank you and any questions ???